sstr

Octreotide (SMS 201-995) is a potent inhibitor of growth hormone, glucagon, and insulin.

Octreotide Acetate (Sandostatin) is a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone.

Paltusotine is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability. Paltusotine maintains GH and IGF-1 levels in acromegaly patients

Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.

SSTR5 antagonist 1 is a selective, and orally available antagonist of somatostatin receptor subtype 5 (SSTR5)(IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively).

SSTR5 antagonist 2 is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5),with potential to treat type 2 diabetes mellitus (T2DM).

SSTR5 antagonist 2 TFA is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5), with potential to treat type 2 diabetes mellitus (T2DM).

Octreotide, a cyclic SSTR agonist, serves as the cyclic Somatostatin Receptor SSTR agonist [1].

SSTR4agonist-1 (Compound 47) is a selective agonist of the somatostatin receptor 4 (SSTR4), with an EC50 of 4.7 nM. It has a half-life of over 130 minutes in human liver microsomes.

SSTR4 agonist5 (Compound 5) is an orally active agonist of the somatostatin receptor 4 (SSTR4) with an EC50 of 0.228 nM. It demonstrates good stability in human/rat liver microsomes and can inhibit mechanical hyperalgesia in rat models.

SSTR4 agonist6 (Compound 1) is an agonist of SSTR4 that can be used in pain research.

SSTR5 antagonist4 (compound 1) is a potent, highly selective, and orally bioavailable antagonist of somatostatin subtype 5 (SSTR5) with an hSSTR5 IC50 of 1.3 nM and an mSSTR5 IC50 of 1.0 nM. It has demonstrated effectiveness in oral glucose tolerance tests (OGTT) in high-fat diet (HFD) mice and is applicable in research related to type 2 diabetes.

SSTR4 agonist 2 is a potent somatostatin receptor subtype 4 (SSTR4) agonist with potential applications in research on SSTR4-related medical disorders. The SSTR4 pathway inhibits nociceptive and inflammatory processes [1].

SSTR4 agonist 4 is a potent SSTR4 agonist with potential applications in pain research. SSTR4 agonists demonstrate efficacy in rodent models of pain associated with acute and chronic anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, regions involved in memory and learning, and in Alzheimer's disease pathology [1].

SSTR4 agonist 3 is a potent compound that activates the SSTR4 receptor, which is highly expressed in the hippocampus and neocortex—regions associated with memory, learning, and Alzheimer's disease pathology. SSTR4 agonists demonstrate strong efficacy in rodent models of both acute and chronic pain by reducing peripheral nociception and inflammation. Considering its potential application in pain research, SSTR4 agonist 3 is of interest [1].

SSTR5 antagonist 2 hydrochloride is a potent, orally active, selective antagonist of the growth hormone inhibitory hormone (receptor) subtype 5 (SSTR5), with potential for investigation in type 2 diabetes.

SSTR5 antagonist 3 (Compound 23) serves as a potent somatostatin receptor subtype 5 (SSTR5) antagonist, demonstrating oral activity and minimal hERG inhibition. It shows significant efficacy, with IC50 values of 2.8 nM in humans and 1.4 nM in mice. This compound is utilized in gallstone research [1].

SSTR5 antagonist 6, an orally active antagonist specific to the somatostatin receptor subtype 5 (SSTR5), exhibits an IC50 value of 24 nM. This compound is utilized in researching type 2 diabetes [1].

Leupeptin hemisulfate is a protease inhibitor with cell membrane-permeable, reversible, competitive, and oral activities. Leupeptin hemisulfate inhibits the activity of Cathepsin B, Cathepsin H, and Cathepsin L, and blocks fusion of amphipathic lysosomes. Leupeptin hemisulfate also has anti-inflammatory activity.

Kanamycin sulfate (Kanamycin monosulfate) is an aminoglycoside antibiotic that interferes with protein synthesis by binding to the 70S ribosomal subunit of bacteria. Kanamycin sulfate exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as mycoplasmas.

Vapendavir diphosphate (BTA798 diphosphate) is a rhinoceros/enterovirus inhibitor that targets the hydrophobic pocket in the viral capsid and is a capsid-binding agent with antiviral activity that prevents viral entry into the cell. Vapendavir diphosphate inhibits EV71 replication.

MK-4256 is an effective and selective SSTR3 antagonist (IC50s: 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively).

BIM 23056 Acetate is a  potent and surmountable human recombinant sst5 receptor antagonist.

Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors.